Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
1(13%)
Results Posted
80%(4 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
5
63%
Ph not_applicable
1
13%
Ph phase_2
1
13%
Ph phase_3
1
13%

Phase Distribution

5

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
5(62.5%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

1

trials recruiting

Total Trials

8

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(1)

Detailed Status

Completed5
unknown1
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
1
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 15 (62.5%)
Phase 21 (12.5%)
Phase 31 (12.5%)
N/A1 (12.5%)

Trials by Status

completed563%
unknown113%
terminated113%
active_not_recruiting113%

Recent Activity

1 active trials
Showing 5 of 8
active_not_recruitingphase_3

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

NCT04229979
completedphase_2

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

NCT01266083
completedphase_1

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

NCT03761914
completedphase_1

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

NCT01827137
terminatedphase_1

Autologous OC-L Vaccine and Ovarian Cancer

NCT02452775
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT04229979Phase 3

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active Not Recruiting
NCT01266083Phase 2

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Completed
NCT03761914Phase 1

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Completed
NCT01827137Phase 1

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Completed
NCT02452775Phase 1

Autologous OC-L Vaccine and Ovarian Cancer

Terminated
NCT02240537Phase 1

Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer

Unknown
NCT00935545Phase 1

Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors

Completed
NCT00665002Not Applicable

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Completed

All 8 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
8